A new, large-scale study of triple-negative breast cancer shows that small molecules called microRNA can be used to define four subtypes of this aggressive malignancy. The findings, by researchers at The Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC -- James) working with collaborators in Italy, could lead to new screening methods, prognostic markers and perhaps new targeted treatments for this aggressive and often-fatal form of breast cancer.
